Related Experiment Video
Updated: Feb 20, 2026

A Flow Cytometry-Based Cell Surface Protein Binding Assay for Assessing Selectivity and Specificity of an Anticancer Aptamer
Published on: September 13, 2022
Selection and identification of transferrin receptor-specific peptides as recognition probes for cancer cells
Yuyu Tan1, Wenli Liu1, Zhi Zhu2
1MOE Key Laboratory of Spectrochemical Analysis and Instrumentation, Collaborative Innovation Center of Chemistry for Energy Materials, Key Laboratory for Chemical Biology of Fujian Province, State Key Laboratory of Physical Chemistry of Solid Surfaces, College of Chemistry and Chemical Engineering, Xiamen University, Xiamen, Fujian, 361005, China.
Abstract:
Since the transferrin receptor (CD71 or TFRC) is known to be highly expressed in numerous cancers, CD71 has become an attractive target in cancer research. Acquiring specific molecular probes for CD71, such as small molecular ligands, aptamers, peptides, or antibodies, is of great importance for cancer cell recognition and capture. In this work, we chose CD71 as the target for phage display, and after four rounds of positive selection and one round of negative selection, the specific phage library was enriched. After verification and sequence analysis, six peptides were identified to be able to bind to CD71 with high specificity. The specific recognition of the CD71-positive cells was confirmed by flow cytometry and confocal microscopy. Competition experiments demonstrated that peptide Y1 and transferrin (TF) were bound to distinct sites on CD71, indicating that peptide Y1 could replace TF as a potential probe for cell imaging and drug delivery, thus avoiding competition by endogenous TF and side effects. Graphical abstract Six peptides were successfully isolated using in vitro biopanning against CD71 with high specificity and affinity. Peptides Y1 and Y2 would be powerful tools in biosensors and biomedicine due to their unique properties.
Insights
Researchers developed specific peptides targeting the transferrin receptor (CD71) for cancer applications. Peptide Y1 binds to a different site than transferrin, offering potential for improved cell imaging and drug delivery.
Area of Science:
- Biotechnology
- Molecular Biology
- Cancer Research
Background:
- Transferrin receptor (CD71/TFRC) is highly expressed in various cancers.
- Targeting CD71 is crucial for cancer cell recognition and capture.
- Development of specific molecular probes for CD71 is of great importance.
Purpose of the Study:
- To identify specific peptide probes targeting CD71 using phage display.
- To evaluate the binding specificity and potential applications of isolated peptides.
Main Methods:
- Phage display technology with positive and negative selection rounds.
- Peptide verification and sequence analysis.
- Flow cytometry and confocal microscopy for cell recognition confirmation.
- Competition assays to determine binding sites.
Main Results:
- Six peptides with high specificity for CD71 were identified.
- Peptide Y1 and transferrin (TF) bind to distinct sites on CD71.
- Peptide Y1 demonstrated potential as a probe for cell imaging and drug delivery, avoiding endogenous TF competition.
Conclusions:
- Specific peptides targeting CD71 were successfully isolated.
- Peptide Y1 offers a promising alternative to transferrin for CD71-based cancer diagnostics and therapeutics.
- Isolated peptides, particularly Y1 and Y2, show potential for biosensors and biomedical applications.
More Related Videos
08:27Detection of Human Leukocyte Antigen Biomarkers in Breast Cancer Utilizing Label-free Biosensor Technology
Published on: March 24, 2015
07:32Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
Published on: September 30, 2019